KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Equity Average (2016 - 2025)

Historic Equity Average for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to $1.9 billion.

  • CRISPR Therapeutics AG's Equity Average fell 87.67% to $1.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 billion, marking a year-over-year decrease of 87.67%. This contributed to the annual value of $1.9 billion for FY2025, which is 102.26% up from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's Equity Average stood at $1.9 billion, which was down 87.67% from $1.8 billion recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year Equity Average high stood at $2.6 billion for Q3 2021, and its period low was $1.7 billion during Q1 2021.
  • For the 5-year period, CRISPR Therapeutics AG's Equity Average averaged around $2.0 billion, with its median value being $1.9 billion (2024).
  • Its Equity Average has fluctuated over the past 5 years, first soared by 14540.15% in 2021, then plummeted by 2204.53% in 2022.
  • CRISPR Therapeutics AG's Equity Average (Quarter) stood at $2.5 billion in 2021, then fell by 22.05% to $1.9 billion in 2022, then decreased by 5.71% to $1.8 billion in 2023, then rose by 7.23% to $1.9 billion in 2024, then fell by 0.88% to $1.9 billion in 2025.
  • Its Equity Average was $1.9 billion in Q4 2025, compared to $1.8 billion in Q3 2025 and $1.8 billion in Q2 2025.